Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Total Non-current Assets
All assets not expected to be converted to cash within one year.
Apogee Therapeutics, Inc.NASDAQ: APGE
Total Non-current Assets · Q2 FY2026 · quarter ended Jun 2026
Total non-current assets rises 142.9% from a year ago
Total non-current assets stood at $344.08M at the end of Q2 FY2026, up 142.9% from a year earlier and up 56.5% from the prior quarter.
Context
- Total non-current assets amounted to 25.8% of total assets at the end of Q2 FY2026, up 4.2 pp from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +142.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 195.78M USD
- Year-over-year change
- -12.7%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 195.78M | -12.7% |
| FY2024 | 2024-12-31 | 224.24M | +7387.1% |
| FY2023 | 2023-12-31 | 3M | — |
| FY2022 | 2022-12-31 | 0 | — |
Total Non-current Assets vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +142.9% is the 2nd highest of 10, against a peer median of +14.1%.
- Total non-current assets amounts to 25.8% of total assets for APGE, versus a peer median of 20.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥1.02B CNY | -10.8% | -5.1% | 25.7% |
| Mar 2026 | $639M USD | +4.3% | -4.2% | 49.3% | |
| Sep 2026 | $536.6M USD | +13.9% | +28.0% | 31.9% | |
| Jun 2026 | $344.08M USD | +142.9% | — | 25.8% | |
| Mar 2026 | $293.08M USD | +62.7% | +265.2% | 45.7% | |
| Sep 2026 | $239.81M USD | +87.8% | +39.9% | 20.0% | |
| Jun 2026 | $160.76M USD | +23.6% | +16.9% | 15.0% | |
| Jun 2026 | $52.38M USD | +10633.4% | +18.5% | 6.3% | |
| Sep 2026 | $38.94M USD | +14.1% | +290.6% | 3.7% | |
IRONDisc Medicine, Inc. | Sep 2026 | $2.08M USD | -36.6% | +20.3% | 0.3% |
| Peer median (excluding APGE) | — | +14.1% | +20.3% | 20.0% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.